Treatment of Stasis Dermatitis with Peripheral Edema of the Lower Extremities During Calcium Channel Blocker Therapy
This protocol addresses stasis dermatitis occurring alongside peripheral edema of the lower extremities in patients currently receiving calcium channel blocker (e.g., amlodipine) antihypertensive therapy.
Calcium channel blockers increase capillary permeability and, when used as antihypertensive monotherapy, carry a substantial risk of causing peripheral edema — the most common reason for their discontinuation. This medication-associated edema can drive or worsen stasis changes in the lower extremities.
The protocol focuses on the antihypertensive regimen itself. A specific intervention targeting the calcium channel blocker is the central step — the full criteria, sequencing, and alternatives are detailed in the structured protocol.
Reduction of peripheral edema of the lower extremities.
DOI: 10.1007/s40257-022-00753-5
- Antihypertensive medications, such as amlodipine, are CCBs that increase capillary permeability.
- When used as monotherapy, such CCBs are associated with a substantial risk of developing peripheral edema, which is the most common reason for their discontinuation.
- Discontinuing the CCB or switching to an alternative antihypertensive therapy, such as angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, may reduce the associated peripheral edema.